Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

Item
http://www.wikidata.org/entity/Q42510237
A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNAPhase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerThe predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer.Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerA multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.Clinical biomarkers of angiogenesis inhibition.Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.Peripheral nerve reconstruction with collagen tubes filled with denatured autologous muscle tissue in the rat model
P2860

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

Item
http://www.wikidata.org/entity/Q42510237
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@en
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@nl
type
label
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@en
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@nl
prefLabel
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@en
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Circulating VEGF reduction, re ...... ith cetuximab plus irinotecan.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921